GENB GENERATE BIOMEDICINES INC
Health Care · Russell 2000
Next earnings: Tue 10 Nov 2026 · estimated
What 8 analyst firms say about GENERATE BIOMEDICINES INC: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
7 rated views · 8 analyst/firm records · 8 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Fewer than 5 analysts in the last 6 months (4)
- Russell 2000 · Safest consensus · 6MNot scored · Fewer than 5 analysts in the last 6 months (4)
Recent analyst activity · last 90 days
Our tracked history has 5 reports on GENB from 2 analyst firms in the last 90 days (8 firms in the past year).
Comparing each firm's latest target with its previous one: 1 left it unchanged.
No firm's latest available rating differs from its previous one.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Cantor Fitzgerald | Eric Schmidt | Buy | 24 Mar 2026 | — |
| Goldman Sachs | Salveen Richter | Buy | 24 Mar 2026 | Conflicting reports · excluded |
| Guggenheim | Seamus Fernandez | Buy | 24 Mar 2026 | 30.00 USD |
| H.C. Wainwright | Mitchell S. Kapoor | Buy | 30 Oct 2026 | 30.00 USD · 5 Oct 2026 |
| Morgan Stanley | Sean Laaman | Buy | 14 May 2026 | 22.00 USD |
| Piper Sandler | Edward A Tenthoff | Buy | 6 Aug 2026 | 24.00 USD · 24 Mar 2026 |
| Weiss Ratings | Unnamed analyst | — | 25 Sep 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 25 Mar 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 03:30 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.